



# Mantle Cell Lymphoma

Xenograft Tumor Model

MODEL	NOMENCLATURE	HAIR	T CELLS	B CELLS	<b>NK CELLS</b>
SHrN®	NOD.Cg- <i>Prkdc<sup>scid</sup>Hr<sup>hr</sup>/</i> NCrHsd	No	Nonfunctional	Nonfunctional	Impaired

#### MODEL

The SHrN® is a Hairless NOD.SCID Mouse developed by Harlan. Harlan became Envigo in 2015, then Envigo was acquired by Inotiv in 2021. The SHrN® is a triple-immunodeficient model with distinct benefits and excellent for tumor xenografts.


## CELL LINE

Human JeKo-1 cells sourced from ATCC<sup>®</sup> (Number: CRL-3006<sup>™</sup>) were implanted into a cohort of SHrN<sup>®</sup> mice. Female mice at approximately 8 weeks of age were implanted with 1.0e7 cells with GFR Matrigel into the subcutaneous space of the right flank.

## TUMOR GROWTH IN VIVO

The mice were maintained in a barrier under controlled environmental conditions. The mice consumed Teklad Global Rodent Diet 2914 (14% protein). Body weights were taken and tumor measurements were assessed with a caliper twice per week.

#### Tumor Growth Rate for JeKo-1 Cells Inoculated into Female SHrN<sup>®</sup> Mice



Tumor growth study services conducted by Labcorp Drug Development